Simeprevir and sofosbuvir for treatment of hepatitis C infection.
CONCLUSION: Simeprevir and sofasbuvir have advantages in response rates and convenient dosage forms and frequency compared with other HCV treatments; however, they are more expensive than previous HCV therapies.
PMID: 26294237 [PubMed - in process]
Source: American Journal of Health-System Pharmacy : AJHP - Category: Drugs & Pharmacology Authors: Chopp S, Vanderwall R, Hult A, Klepser M Tags: Am J Health Syst Pharm Source Type: research
More News: Cirrhosis | Clinical Trials | Drugs & Pharmacology | Health | Hepatitis | Hepatitis C | Liver | Liver Disease | Pegasys | Urology & Nephrology | Virology